Differential effects of estrogen and testosterone on auditory sensory gating in rats

Psychopharmacology

Volumn 231, Issue 1, 2014, Pages 243-256

  Thwaites, Shane J ^a   Van Den Buuse, Maarten ^a   Gogos, Andrea ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Amphetamine; Apomorphine; Auditory gating; Estrogen; N1; N40; Phencyclidine; Schizophrenia; Sensory gating

Indexed keywords

AMPHETAMINE; APOMORPHINE; DIZOCILPINE; ESTRADIOL; ESTROGEN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; TESTOSTERONE;

AMPLITUDE MODULATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CASTRATION; CONTROLLED STUDY; CORTICAL ELECTRODE; DRUG POTENTIATION; EVENT RELATED POTENTIAL; FEMALE; HEARING IMPAIRMENT; HORMONE SUBSTITUTION; MALE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SEMINAL VESICLE; SENSORY GATING; SHAM PROCEDURE; TREATMENT RESPONSE; UTERUS WEIGHT;

AMPHETAMINE; ANIMALS; APOMORPHINE; AUDITORY PERCEPTION; BODY WEIGHT; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE AGONISTS; ELECTRODES, IMPLANTED; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; ESTROGENS; EVOKED POTENTIALS, AUDITORY; FEMALE; MALE; ORCHIECTOMY; ORGAN SIZE; OVARIECTOMY; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY; SENSORY GATING; SEX CHARACTERISTICS; TESTOSTERONE; UTERUS;

EID: 84891834595     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3231-5     Document Type: Article

References (50)

1. Adler LE, Pachtman E, Franks RD, Pecevich M, Waldo MC, Freedman R (1982) Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol Psychiatry 17:639-654
2. Adler LE, Rose G, Freedman R (1986) Neurophysiological studies of sensory gating in rats: effects of amphetamine, phencyclidine, and haloperidol. Biol Psychiatry 21:787-798
3. Adler LE, Pang K, Gerhardt G, Rose GM (1988) Modulation of the gating of auditory evoked potentials by norepinephrine: pharmacological evidence obtained using a selective neurotoxin. Biol Psychiatry 24:179-190
4. Albert DJ, Jonik RH, Gorzalka BB, Newlove T, Webb B, Walsh ML (1991) Serum estradiol concentration required to maintain body weight, attractivity, proceptivity, and receptivity in the ovariectomized female rat. Physiol Behav 49:225-231
5. Anderer P, Semlitsch HV, Saletu B, Saletu-Zyhlarz G, Gruber D, Metka M, Huber J, Graser T, Oettel M (2003) Effects of hormone replacement therapy on perceptual and cognitive event-related potentials in menopausal insomnia. Psychoneuroendocrinology 28:419-445
6. Becker J, Gomes I, Ghisolfi ES, Schuch A, Ramos FLP, Ehlers JA, Nora DB, Lara DR, da Costa JC (2004) Clozapine, but not typical antipsychotics, correct P50 suppression deficit in patients with schizophrenia. Clin Neurophysiol 115:396-401
7. Bickford-Wimer PC, Nagamoto H, Johnson R, Adler LE, Egan M, Rose GM, Freedman R (1990) Auditory sensory gating in hippocampal neurons: a model system in the rat. Biol Psychiatry 27:183-192
8. Bisagno V, Ferguson D, Luine VN (2003) Chronic D-amphetamine induces sexually dimorphic effects on locomotion, recognition memory, and brain monoamines. Pharmacol Biochem Behav 74:859-867
9. Boutros NN, Bonnet KA, Millana R, Liu J (1997) A parametric study of the N40 auditory evoked response in rats. Biol Psychiatry 42:1051-1059
10. Boutros NN, Brockhaus-Dumke A, Gjini K, Vedeniapin A, Elfakhani M, Burroughs S, Keshavan M (2009) Sensory-gating deficit of the N100 mid-latency auditory evoked potential in medicated schizophrenia patients. Schizophr Res 113:339-346
11. Breier MR, Lewis B, Shoemaker JM, Light GA, Swerdlow NR (2010) Sensory and sensorimotor gating-disruptive effects of apomorphine in Sprague Dawley and Long Evans rats. Behav Brain Res 208:560-565
12. Brenner CA, Edwards CR, Carroll CA, Kieffaber PD, Hetrick WP (2004) P50 and acoustic startle gating are not related in healthy participants. Psychophysiology 41:702-708
13. Cadenhead KS, Light GA, Shafer KM, Braff DL (2005) P50 suppression in individuals at risk for schizophrenia: the convergence of clinical, familial, and vulnerability marker risk assessment. Biol Psychiatry 57:1504-1509
14. Carlsson A, Waters N, Carlsson ML (1999) Neurotransmitter interactions in schizophrenia - therapeutic implications. Biol Psychiatry 46:1388-1395
15. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML (2001) Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 41:237-260
16. Chavez C, Hollaus M, Scarr E, Pavey G, Gogos A, van den Buuse M (2010) The effect of estrogen on dopamine and serotonin receptor and transporter levels in the brain: an autoradiography study. Brain Res 1321:51-59
17. Chua W, de Izquierdo Santiago A, Kulkarni J, Mortimer A (2004) Oestrogen for schizophrenia (Protocol). Cochrane Database Syst Rev (Issue 1):2004
18. Dalecki A, Croft RJ, Johnstone SJ (2011) An evaluation of P50 paired-click methodologies. Psychophysiology 48:1692-1700
19. Delorme A, Makeig S (2004) EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysis. J Neurosci Methods 134:9-21
20. Di Paolo T (1994) Modulation of brain dopamine transmission by sex steroids. Rev Neurosci 5:27-41
21. Dissanayake DW, Zachariou M, Marsden CA, Mason R (2009) Effects of phencyclidine on auditory gating in the rat hippocampus and the medial prefrontal cortex. Brain Res 1298:153-160
22. Garcia-Segura LM, Azcoitia I, DonCarlos LL (2001) Neuroprotection by estradiol. Prog Neurobiol 63:29-60
23. Gogos A, van den Buuse M (2003) Castration reduces the effect of serotonin-1A receptor stimulation on prepulse inhibition in rats. Behav Neurosci 117:1407-1415
24. Gogos A, Van den Buuse M (2004) Estrogen and progesterone prevent disruption of prepulse inhibition by the serotonin-1A receptor agonist 8-hydroxy-2-dipropylaminotetralin. J Pharmacol Exp Ther 309:267-274
25. Gogos A, Kwek P, Chavez C, van den Buuse M (2010)Estrogen treatment blocks 8-hydroxy-2-dipropylaminotetralin- and apomorphine-induced disruptions of prepulse inhibition: involvement of dopamine D1 or D2 or serotonin 5-HT1A, 5-HT2A, or 5-HT7 receptors. J Pharmacol Exp Ther 333:218-227
26. Gogos A, Kwek P, van den Buuse M (2011) The role of estrogen and testosterone in female rats in behavioral models of relevance to schizophrenia. Psychopharmacology (Berl) 219:213-224
27. Hafner H (2003) Gender differences in schizophrenia. Psychoneuroendocrinology 28(Suppl 2):17-54
28. Jansen BH, Hu L, Boutros NN (2010) Auditory evoked potential variability in healthy and schizophrenia subjects. Clin Neurophysiol 121:1233-1239
29. Keedy SK, Marlow-O'Connor M, Beenken B, Dorflinger J, Abel M, Erwin RJ (2007) Noradrenergic antagonism of the P13 and N40 components of the rat auditory evoked potential. Psychopharmacology (Berl) 190:117-125
30. Kluck N, O'Connor S, Hesselbrock V, Tasman A, Maier D, Bauer L (1992) Variation in evoked potential measures over the menstrual cycle: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 16:901-911
31. Kokkinidis L, Anisman H (1980) Amphetamine models of paranoid schizophrenia: an overview and elaboration of animal experimentation. Psychol Bull 88:551-579
32. Kulkarni J, Riedel A, de Castella AR, Fitzgerald PB, Rolfe TJ, Taffe J, Burger H (2001) Estrogen - a potential treatment for schizophrenia. Schizophr Res 48:137-144
33. Light GA, Braff DL (1999) Human and animal studies of schizophrenia-related gating deficits. Curr Psychiatr Rep 1:31-40
34. Light GA, Geyer MA, Clementz BA, Cadenhead KS, Braff DL (2000) Normal P50 suppression in schizophrenia treated with atypical antipsychotic medications. Am J Psychiatr 157:767-771
35. Light GA, Williams LE, Minow F, Sprock J, Rissling A, Sharp R, Swerdlow NR, Braff DL (2010) Electroencephalography (EEG) and event-related potentials (ERPs) with human participants. Current Protocols in Neuroscience Chapter 6: Unit 6 25 1-24.
36. Morris BJ, Cochran SM, Pratt JA (2005) PCP: from pharmacology to modelling schizophrenia. Curr Opin Pharmacol 5:101-106
37. Oades RD, Schepker R (1994) Serum gonadal steroid hormones in young schizophrenic patients. Psychoneuroendocrinology 19:373-385
38. Olincy A, Braff DL, Adler LE, Cadenhead KS, Calkins ME, Dobie DJ, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Wagner BD, Freedman R (2010) Inhibition of the P50 cerebral evoked response to repeated auditory stimuli: results from the Consortium on Genetics of Schizophrenia. Schizophr Res 119:175-182
39. Oranje B, Aggernaes B, Rasmussen H, Ebdrup BH, Glenthøj BY (2013) P50 suppression and its neural generators in antipsychotic-naïve first-episode schizophrenia before and after 6 months of quetiapine treatment. Schizophr Bull 39:472-480
40. Patterson JV, Hetrick WP, Boutros NN, Jin Y, Sandman C, Stern H, Potkin S, Bunney WE (2008) P50 sensory gating ratios in schizophrenics and controls: a review and data analysis. Psychiatry Res 158:226-247
41. Riecher-Rossler A, Hafner H, Stumbaum M, Maurer K, Schmidt R (1994) Can estradiol modulate schizophrenic symptomatology? Schizophr Bull 20:203-214
42. Sanchez MG, Bourque M, Morissette M, di Paolo T (2010) Steroids-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 16:e43-e71
43. Schank JC (2001) Do Norway rats (Rattus norvegicus) synchronize their estrous cycles? Physiol Behav 72:129-139
44. Simpson J, Kelly JP (2012) An investigation of whether there are sex differences in certain behavioural and neurochemical parameters in the rat. Behav Brain Res 229:289-300
45. Stevens KE, Fuller LL, Rose GM (1991) Dopaminergic and noradrenergic modulation of amphetamine-induced changes in auditory gating. Brain Res 555:91-98
46. Svenningsson P, Tzavara ET, Carruthers R, Rachleff I, Wattler S, Nehls M, McKinzie DL, Fienberg AA, Nomikos GG, Greengard P (2003) Diverse psychotomimetics act through a common signaling pathway. Science 302:1412-1415
47. Swerdlow NR, Geyer MA, Shoemaker JM, Light GA, Braff DL, Stevens KE, Sharp R, Breier M, Neary A, Auerbach PP (2006) Convergence and divergence in the neurochemical regulation of prepulse inhibition of startle and N40 suppression in rats. Neuropsychopharmacology 31:506-515
48. Venables PH (1964) Input dysfunction in schizophrenia. Prog Exp Pers Res 72:1-47
49. Wada Y, Takizawa Y, Jiang ZY, Yamaguchi N (1994) Gender differences in quantitative EEG at rest and during photic stimulation in normal young adults. Clin Electroencephalogr 25:81-85
50. Waldo MC, Graze K, de Graff Bender S, Adler LE, Freedman R (1987) Premenstrual mood changes and gating of the auditory evoked potential. Psychoneuroendocrinology 12:35-40